Tagged with Opinion

UK Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical industry’s rapid response to COVID-19 and the three ways in which the sector is driving national innovation forwards.   With the upheaval of recent months, businesses up and down the UK have been forced to adapt…

USA Dan Leonard, Kimberly Westrich, and Brian Sils of the National Pharmaceutical Council examine how a new HHS ruling on how US patients pay for medicines could hurt them financially, exacerbating what is already a challenging time in the midst of the COVID-19 pandemic.   The pandemic has been a challenging…

Opinion Dr Sophia Ononye-Onyia explains why a combination of both repurposed drugs and emerging technologies like 3D bioprinting and artificial intelligence will be crucial in beating COVID-19.   Much has already been said about the hundreds of vaccines that are currently in development for providing global protection against COVID-19 by leading…

China I recently had the pleasure to moderate an event on the COVID-19 impact on the relationship between Doctor and Patient, attended by 50 executives of the French Healthcare community in China (Club Santé Chine). I would like to share here some learnings and personal thoughts.   One of the consequences…

Global ‘The Key Challenges: Life Sciences and Healthcare 2020’ is the latest report from Cornerstone International Group based on a global survey of stakeholders from across the life sciences healthcare (LSH) industry. The following is an extract on leadership. Click here to read the full report.   The first impression listening to…

Opinion John G. Singer outlines why a focus on patients’ adherence to their medication is not necessarily useful in working to improve health outcomes and why innovation is more sorely needed in markets and strategies, not technologies and analytics.   “Monty Python and the Holy Grail,” which opened yesterday at the…

Global ‘The Key Challenges: Life Sciences and Healthcare 2020’ is the latest report from Cornerstone International Group based on a global survey of stakeholders from across the life sciences healthcare (LSH) industry. The following is an extract on strategy. Click here to read the full report.   Compared to other businesses,…

Opinion Mike Glover, Vice President Global Head of Access and Pricing Strategy Oncology at GSK outlines that while new mathematical approaches to health technology assessment (HTA) have been hugely beneficial, a broader approach that includes the insights of individual people is necessary to truly drive forward better health outcomes.   The…

Opinion Brendan Shaw takes a look at the rise of drone technology in medical product delivery and its implications for the future of healthcare.   What was once thought of as science fiction even a few years ago is rapidly becoming a commercial reality. While we have not yet seen regular…

Coronavirus IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19 treatment; highlighting the unprecedented levels of collaboration being demonstrated as key industry players work towards a common goal.*   Last week, high-level representatives from seven companies…

Opinion DataArt’s Daniel Piekarz looks at how machine learning and artificial intelligence can play into the important task of drug repurposing, potentially providing solutions to the most pressing healthcare concerns of today, including the COVID-19 pandemic.   “Standing on the shoulders of giants” is a metaphor, made famous by Isaac Newton,…

Opinion Dr Neil Cashman examines the recent news around Biogen’s Alzheimer’s treatment aducanumab, assuages some investor fears, and underlines the treatment’s solid fundamentals and potential.    On April 2020, Biogen initiated regulatory review for aducanumab, its investigational therapy for Alzheimer’s disease. Investors reacted negatively, and this reverberated throughout the Alzheimer’s research…